Keyphrases
Head-and-neck Squamous Cell Carcinoma (HNSCC)
94%
Positron Emission Tomography-computed Tomography (PET-CT)
82%
Positron Emission Tomography
65%
18F-fluorodeoxyglucose (18F-FDG)
62%
PET-MRI
62%
Non-small Cell Lung Cancer (NSCLC)
43%
Head-and-neck Cancer
41%
Positron Emission tomography-CT
37%
Fludeoxyglucose
33%
Regional Failure
31%
Lung Cancer
30%
Standardized Uptake Value
29%
Lung Cancer Staging
29%
Cancer Patients
29%
Patient Assessment
27%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
25%
Small Cell Lung Cancer
24%
FDG Positron Emission Tomography
24%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
24%
Dose Painting
24%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
23%
Tumor
23%
Malignancy
23%
Distant Metastasis
22%
MRI Scan
21%
Hazard Ratio
21%
FDG Uptake
21%
MR-based Attenuation Correction
21%
FDG PET-CT
21%
Response Evaluation
21%
Radiation Dose
18%
Cisplatin
18%
Confidence Interval
18%
Chemotherapy
17%
CT-MRI
17%
SUVmax
16%
Computed Tomography
16%
Prognostic Model
15%
Medicine and Dentistry
positron emission tomographic scan
100%
Polyethylene Terephthalate
94%
Positron Emission Tomography-Computed Tomography
93%
Head and Neck Squamous Cell Carcinoma
81%
Lung Cancer
66%
Non Small Cell Lung Cancer
47%
Neoplasm
45%
Positron Emission Tomography - Magnetic Resonance Imaging
37%
P16
36%
Standardized Uptake Value
35%
Chemoradiotherapy
35%
Reproducibility
30%
Prospective Study
29%
Fluorodeoxyglucose F 18
29%
Molecular Imaging
28%
Head and Neck Cancer
27%
Bone Scintigraphy
24%
Hazard Ratio
24%
Biological Marker
24%
Small Cell Lung Cancer
24%
Non-Small Cell Lung Cancer
24%
Cancer
24%
Computer Assisted Tomography
22%
Fluorine-18
19%
Proportional Hazards Model
19%
Diagnosis
19%
Cisplatin
18%
Health Care Cost
17%
Cost-Effectiveness Analysis
17%
Radiation Therapy
16%
Tubulin
15%
Neck
15%
Protein P53
15%
